1. Home
  2. THE CING
  3. Clinical Sciences
  4. Neuroscience Department
  5. Research
  6. Selected Publications

Neuroscience Department

Selected Publications

Selected publications of the Neuroscience Department in the last 5 years:

  1. Stavrou M, Kleopa KA. CMT1A current gene therapy approaches and promising biomarkers. Neural Regen Res. 2023 Jul;18(7):1434-1440. 
  2. Jennings MJ, Kagiava A, Vendredy L, Spaulding EL, Stavrou M, Hathazi D, Grüneboom A, De Winter V, Gess B, Schara U, Pogoryelova O, Lochmüller H, Borchers CH, Roos A, Burgess RW, Timmerman V, Kleopa KA, Horvath R. NCAM1 and GDF15 are biomarkers of Charcot-Marie-Tooth disease in patients and mice. Brain. 2022 Nov 21;145(11):3999-4015. 
  3. Antoniou A, Giannakou M, Georgiou E, Kleopa KA, Damianou C. Robotic device for transcranial focussed ultrasound applications in small animal models. Int J Med Robot. 2022 Dec;18(6):e2447. 
  4. Stavrou M, Kagiava A, Choudury SG, Jennings MJ, Wallace LM, Fowler AM, Heslegrave A, Richter J, Tryfonos C, Christodoulou C, Zetterberg H, Horvath R, Harper SQ, Kleopa KA. A translatable RNAi-driven gene therapy silences PMP22/Pmp22 genes and improves neuropathy in CMT1A mice. J Clin Invest. 2022 Jul 1;132(13):e159814. 
  5. Kagiava A, Richter J, Tryfonos C, Leal-Julià M, Sargiannidou I, Christodoulou C, Bosch A, Kleopa KA. Efficacy of AAV serotypes to target Schwann cells after intrathecal and intravenous delivery. Sci Rep. 2021 Dec 2;11(1):23358. 
  6. Stavropoulos F, Sargiannidou I, Potamiti L, Kagiava A, Panayiotidis MI, Bae JH, Yeom SC, Lee JY, Kleopa KA. Aberrant Mitochondrial Dynamics and Exacerbated Response to Neuroinflammation in a Novel Mouse Model of CMT2A. Int J Mol Sci. 2021 Oct 26;22(21):11569. 
  7. Stavrou M, Sargiannidou I, Georgiou E, Kagiava A, Kleopa KA. Emerging Therapies for Charcot-Marie-Tooth Inherited Neuropathies. Int J Mol Sci. 2021 Jun 3;22(11):6048.
  8. Stavropoulos F, Georgiou E, Sargiannidou I, Kleopa KA. Dysregulation of Blood-Brain Barrier and Exacerbated Inflammatory Response in Cx47-Deficient Mice after Induction of EAE.  Pharmaceuticals (Basel). 2021 Jun 28;14(7):621. 
  9. Sargiannidou I, Christophidou-Anastasiadou V, Hadjisavvas A, Tanteles GA, Kleopa KA. Novel GJA1/Cx43 Variant Associated With Oculo-Dento-Digital Dysplasia Syndrome: Clinical Phenotype and Cellular Mechanisms. Front Genet. 2021 Jan 27;11:604806. 
  10. Kagiava A, Karaiskos C, Richter J, Tryfonos C, Jennings MJ, Heslegrave AJ, Sargiannidou I, Stavrou M, Zetterberg H, Reilly MM, Christodoulou C, Horvath R, Kleopa KA. AAV9-mediated Schwann cell-targeted gene therapy rescues a model of demyelinating neuropathy. Gene Ther. 2021;28(10-11):659-675. 
  11. Stavrou M, Sargiannidou I, Christofi T, Kleopa KA. Genetic mechanisms of peripheral nerve disease.  Neurosci Lett. 2021 Jan 18;742:135357. 
  12. Sargiannidou I, Kagiava A, Kleopa KA. Gene therapy approaches targeting Schwann cells for demyelinating neuropathies. Brain Res. 2020, Feb 1;1728:146572. 
  13. Kagiava A, Richter J, Tryfonos C, Karaiskos C, Heslegrave AJ, Sargiannidou I, Rossor AM, Zetterberg H, Reilly MM, Christodoulou C, Kleopa KA. Gene replacement therapy after neuropathy onset provides therapeutic benefit in a model of CMT1X. Hum Mol Genet. 2019, 28: 3528-3542.
  14. Papaneophytou CP, Georgiou E, Kleopa KA. Regulatory role of oligodendrocyte gap junctions in inflammatory demyelination. Channels 2019, 13(1):247-263. 
  15. Schiza N, Georgiou E, Kagiava A, Médard J-J, Richter J, Tryfonos C, Sargiannidou I, Heslegrave AJ, Rossor AM, Zetterberg H, Reilly MM,  Christodoulou C, Chrast R, Kleopa KA. Gene replacement therapy in a model of Charcot-Marie-Tooth 4C neuropathy, BRAIN 2019, 142(5):1227-1241.  
  16. Papaneophytou CP, Georgiou E, Karaiskos C,  Sargiannidou I, Markoullis K, Mona Freidin M, Abrams CK, Kleopa KA. Regulatory role of oligodendrocyte gap junctions in inflammatory demyelination. Glia 2018, 66(12):2589-2603.
  17. Kyriakoudi S, Sargiannidou I, Kagiava A, Olympiou M, Kleopa KA.Golgi-retained Cx32 mutants interfere with gene addition therapy for CMT1X. Hum Mol Genet. 2017 26(9):1622-163
  18. Georgiou E, Sidiropoulou K, Richter J, Papaneophytou C, Sargiannidou I, Kagiava A, von Jonquieres G, Christodoulou C, Klugmann M, Kleopa KA. Gene therapy targeting oligodendrocytes provides therapeutic benefit in a leukodystrophy model, Brain 2017, 140(3):599-616 
     
Related Articles
Research Grants

Research Grants to the Neuroscience Department in the last 5 years

Awards

Selected Awards to Members of the Neuroscience Department in the last 5 years:    •    European Academy of Neurology Investigator Award 2015 to Kleopas ...

winner